

Synthesis of Schiff Bases from 2-Amino-4, 6-diphenyl Pyrimidines and 2-Amino-4,6-Diphenyl-5,6-Dihydro Pyrimidines and Evaluation of Antimicrobial and Anticancer Activities

MRS. ANJALI MILIND RAHATGAONKAR and B.J. GHIYA
*Chemistry Department
Institute of Science, Nagpur-440 001, India*

Schiff bases were prepared by the condensation of 2-amino-diaryl pyrimidines and 2-amino-diaryl-dihydro pyrimidines with substituted benzaldehydes in ethanol with 2-3 drops of H₂SO₄ as a condensing agent. The synthesised pyrimidines and their Schiff bases were further studied for the evaluation of antimicrobial and anticancer activities.

INTRODUCTION

The biological significance of the pyrimidine derivatives has led us to the synthesis of substituted pyrimidines. As pyrimidine is a basic nucleus in DNA and RNA, it has been found to be associated with diverse biological activities¹. Many of the Schiff bases exhibit anticancer and antitubercular activities² as well as anti-microbial activities. Synthesis of Schiff bases has been reported by condensation of aniline with substituted benzaldehydes³. Ahluwalia and coworkers⁴ have synthesised 2-amino pyrimidines which were evaluated as antibacterial agents.

2-Amino-4,6-diphenyl pyrimidines and 2-amino-4,6-diphenyl-5,6-dihydro pyrimidines were prepared from dibenzoyl methanes and chalcones respectively with guanidine carbonate in ethylene glycol and DMF.

Further it was condensed with differentyl substituted aromatic aldehydes to get corresponding Schiff bases (4). Some of the compounds have been screened for anticancer, as well as for antimicrobial activities.

EXPERIMENTAL

All the melting points were determined in open capillaries and are uncorrected. The IR spectra (KBr) were recorded on Philips PV 9700 spectrophotometer. The ¹H-NMR spectra were recorded on Ac-Brucker 300 MHz spectrophotometer using 5 mm tubes.

General Procedure

2'-Hydroxy-5'-substituted chalcones (2) have already been reported⁵.

Preparation of 2-Amino-5,6-dihydro-4,6-diaryl pyrimidine (3)

A mixture of (2) (0.01 mol) and guanidine carbonate (0.04 mol) was taken in 100 mL R.B. flask and 30 mL of DMF was added to it. The reaction mixture was refluxed for 3 h and kept overnight for completion of reaction. Then the reaction


mixture was diluted with water. The resulting solid was washed, filtered and dried. Further it was crystallized from ethanol : dioxane (4 : 1 mixture) for getting compound (3) [Table-1 Scheme I].

TABLE-1

Comp.	R ₁	R ₂	R ₃	R ₄	Analysis (%)			Mol formula (m.p., °C)
					C	H	N	
3a	CH ₃	H	—	—	73.0	5.20	15.0	C ₁₇ H ₁₆ N ₃ O (174)
3b	CH ₃	OCH ₃	—	—	71.0	5.90	13.9	C ₁₈ H ₁₈ N ₃ O ₂ (221)
3c	Cl	H	—	—	65.0	4.20	14.1	C ₁₆ H ₁₃ N ₃ OCl (211)
3d	Cl	OCH ₃	—	—	60.1	4.70	13.5	C ₁₆ H ₁₅ N ₃ O ₂ Cl (196)
4a ₁	CH ₃	H	H	H	78.6	5.6	11.7	C ₂₄ H ₂₀ N ₃ O (210)
4a ₂	CH ₃	H	H	OCH ₃	76.0	5.3	10.7	C ₂₅ H ₂₂ N ₃ O ₂ (214)
4a ₃	CH ₃	H	NO ₂	H	71.0	4.2	10.4	C ₂₄ H ₁₉ N ₄ O ₃ (211)
4a ₄	CH ₃	H	H	OH	76.0	5.2	10.8	C ₂₄ H ₂₀ N ₃ O ₂ (225)
4a ₅	CH ₃	H	H	N < $\begin{matrix} \text{CH}_3 \\ \text{CH}_3 \end{matrix}$	76.2	6.3	13.6	C ₂₆ H ₂₅ N ₄ O (230)
4b ₁	CH ₃	OCH ₃	H	H	75.9	5.6	10.6	C ₂₅ H ₂₂ N ₃ O ₂ (235)
4b ₂	CH ₃	OCH ₃	H	OCH ₃	73.9	7.3	9.9	C ₂₆ H ₂₄ N ₃ O ₃ (250)
4b ₃	CH ₃	OCH ₃	NO ₂	H	69.2	4.9	12.7	C ₂₅ H ₂₁ N ₄ O ₄ (258)
4b ₄	CH ₃	OCH ₃	H	OH	72.9	5.4	10.1	C ₂₅ H ₂₂ N ₃ O ₃ (248)
4b ₅	CH ₃	OCH ₃	H	N < $\begin{matrix} \text{CH}_3 \\ \text{CH}_3 \end{matrix}$	74.1	6.4	12.9	C ₂₇ H ₂₇ N ₄ O ₂ (260)
4c ₁	Cl	H	H	H	72.10	4.3	10.9	C ₂₃ H ₁₇ N ₃ OCl (221)
4c ₂	Cl	H	H	OCH ₃	69.90	4.6	10.9	C ₂₄ H ₁₉ N ₃ O ₂ Cl (220)
4c ₃	Cl	H	NO ₂	H	64.03	3.9	12.7	C ₂₃ H ₁₆ N ₄ O ₃ Cl (218)
4c ₄	Cl	H	H	OH	68.90	4.3	10.5	C ₂₃ H ₁₇ N ₃ O ₂ Cl (227)
4c ₅	Cl	H	H	N < $\begin{matrix} \text{CH}_3 \\ \text{CH}_3 \end{matrix}$	69.60	5.3	14.0	C ₂₅ H ₂₂ N ₄ OCl (232)
4d ₁	Cl	OCH ₃	H	H	69.10	4.6	10.03	C ₂₄ H ₁₉ N ₃ O ₂ Cl (228)
4d ₂	Cl	OCH ₃	H	OCH ₃	68.30	4.9	9.7	C ₂₅ H ₂₁ N ₃ O ₃ Cl (230)
4d ₃	Cl	OCH ₃	NO ₂	H	64.90	3.7	13.1	C ₂₄ H ₁₈ N ₄ O ₃ Cl (190)
4d ₄	Cl	OCH ₃	H	OH	63.40	4.2	8.9	C ₂₄ H ₁₉ N ₃ O ₃ Cl (218)
4d ₅	Cl	OCH ₃	H	N < $\begin{matrix} \text{CH}_3 \\ \text{CH}_3 \end{matrix}$	67.30	5.6	12.1	C ₂₆ H ₂₄ N ₄ O ₂ Cl (240)

(3b) IR, λ cm⁻¹: 3460 ν (OH), 3350 ν (NH), 1630 ν (C=C), 1580 ν (C=N) 1540 ν (NH bending), 1240 ν (Ar—O).

NMR (3b): (CDCl₃ + DMSO-d₆): δ (2.34, S, 3H, Ar—CH₃), (3.8, S, 3H,




Ar—OCH₃), (6.62, s, 2H, NH₂), (7.11, dd, 1H, H_f), (6.82, d, 2H, H_b, H_c), (7.52, s, 1H, H_a), (7.77, s, 1H, H_f), (7.006, d, 2H, H_{d'}, H_{e'}), (8.1, d, 2H, H_d, H_e), (13.83, s, 1H, Ar—OH).

2-Imino-benzal 5,6-dihydro 4,6-diaryl pyrimidines (4)

A mixture of (3) (0.001 mol) and substituted aromatic aldehyde (0.001 mol) was taken in ethanol (10 mL) in R.B. flask. A drop of conc. H₂SO₄ was added to it. The reaction mixture was refluxed for about 1/2 h on water bath. A bright yellow coloured compound separated was filtered hot. The compound was recrystallized from ethanol (Table-1) (Scheme II).

(4b₅) IR, λ cm⁻¹-3340 ν (OH), 1685 ν (C=N), 1620 ν (C=C), 1585 ν (C=N stretching), 1250 ν (Ar—O)

NMR (4b₅): (CDCl₃ + DMSO-d₆) - δ (2.36, s, 3H, Ar—CH₃), (3.91, s, 3H, Ar—OCH₃), (5.15, b, 6H, N < $\begin{matrix} \text{CH}_3 \\ \text{CH}_3 \end{matrix}$), (6.96, d, 1H, H_b), (7.1, d, 2H, H_d, H_e), (7.27, d, 1H, H_c), (7.68, s, H, N=CH), (7.80, s, H, H_a), (7.86, s, 1H, H_f), (7.15, d, 2H, H_{d'}, H_{e'}), (8.35, b, 1H, NH).



Preparation of 2-amino-4,6-diaryl pyrimidine (5)

A mixture of (I) (0.01 mol) and guanidine carbonate (0.04 mol) was taken in 100 mL R.B. flask and ethylene glycol was added to it. The reaction mixture was refluxed for 3 h and kept overnight for completion of reaction. Then the reaction mixture was diluted with water. The resulting solid was washed, filtered and dried. Further it was crystallised.

IR (KBr) cm^{-1} (5b): 3350 $\nu(\text{N—H})$, 1630 $\nu(\text{C}=\text{C})$, 1580 $\nu(\text{C}=\text{N—})$, 1540 $\nu(\text{N—H bending})$, 1580 $\nu(\text{C}=\text{N—})$, Stretching in cyclic system).

(5b) $^1\text{H NMR}$ δ ($\text{CDCl}_3 + \text{DMSO-d}_6$): 3.83 (OCH_3), 6.07 (NH_2), 6.44–8.05 (Ar—H), 14.34 (O—H), 7.37 ($\text{Ar—H of pyrimidine}$).

2-Imino-benzal,4,6-diaryl pyrimidines (6)

A mixture of (5) (0.001 mol) and substituted aromatic aldehyde (0.001 mol) was taken in ethanol (10 mL) in R.B. flask. A drop of conc. H_2SO_4 was added to it. The reaction mixture was refluxed for about 1/2 h on water bath. A bright yellow coloured compound separated was filtered hot. The compound was recrystallized from ethanol.

(6d) IR (KBr) cm^{-1} : 1685 $\nu(\text{C}=\text{N})$; 1620 $\nu(\text{C}=\text{C})$; 1585 $\nu(\text{C}=\text{N—})$ stretching in cyclic system)

Absence of N—H stretching band which appears at 3350 cm^{-1} in 5d is a clear indication that the condensation has taken place. A strong and sharp band appearing at 1685 cm^{-1} again supports the condensation between (5b) and benzaldehyde.

$^1\text{H NMR}$, δ (DMSO-d_6): 3.87 (OCH_3), 3.90 (OCH_3), 7.54 (N—CH), 7.79 ($\text{Ar—H of pyrimidine}$), 6.5–8.06 (Ar—H).

The physical data of compounds 5 and 6 are presented in Table-2.

Anti-microbial Activity

The synthesised compounds were tested for antimicrobial activity by using DMF as solvent against *S. aureus*, *E. coli*, *P. aeruginosa*, *K. pneumoniae* at 100 µg. The zone of inhibition with respect to controlled medium is illustrated in Table-3. The sensitivity of the compounds against the said microbes was compared with standard drug as penicilin. Zone of inhibition was measured in mm.

TABLE-2
PHYSICAL DATA OF COMPOUNDS 5 AND 6

Comp. No.	R	R ₁	R ₂	R ₃	R ₄	m.p. (°C)	Yield (%)
5a	OCH ₃	H	H	—	—	180	62
5b	OCH ₃	H	H	—	—	225	60
5c	H	CH ₃	H	—	—	180	80
5d	H	Cl	H	—	—	201	80
6a	OCH ₃	H	H	H	H	263	95
6b	OCH ₃	H	H	H	OCH ₃	265	92
6c	OCH ₃	H	H	NO ₂	H	267	95
6d	OCH ₃	H	OCH ₃	H	H	267	95
6e	OCH ₃	H	OCH ₃	H	OCH ₃	265	95
6f	OCH ₃	H	OCH ₃	NO ₂	H	270	90
6g	H	CH ₃	H	H	H	210	90
6h	H	CH ₃	H	H	OCH ₃	240	90
6i	H	CH ₃	H	NO ₂	H	195	90
6j	H	CH ₃	H	H	OH	225	90
6k	H	CH ₃	H	H	N < $\begin{matrix} \text{CH}_3 \\ \text{CH}_3 \end{matrix}$	230	90
6l	H	Cl	H	H	H	205	90
6m	H	Cl	H	H	OCH ₃	218	90
6n	H	Cl	H	NO ₂	H	215	90
6o	H	Cl	H	H	OH	223	90
6p	H	Cl	H	H	N < $\begin{matrix} \text{CH}_3 \\ \text{CH}_3 \end{matrix}$	217	90

TABLE-3

Comp.	<i>E. coli</i>	<i>S. aureus</i>	<i>P. aeruginosa</i>	<i>K. pneumoniae</i>
3c	n.i.	n.i.	n.i.	8
4d ₁	6	8	n.i.	7
4d ₂	6	7	n.i.	n.i.
4d ₃	6	6	n.i.	6
4d ₄	6	8	n.i.	n.i.

n.i. = not inhibited; all zone of inhibition are in mm.

TABLE-4

Comp	<i>E. coli</i>	<i>S. aureus</i>	<i>B. subtilis</i>	<i>P. aeruginosa</i>	<i>K. Pneumoniae</i>
5a	4	5	5.0	—	—
5b	n.i.	1	n.i.	—	—
5c	11	n.i.	—	10	7.0
5d	n.i.	n.i.	—	n.i.	n.i.
6a	5	6.4	10.3	—	—
6b	4	4.2	5.0	—	—
6c	4	5.4	10.5	—	—
6d	7	6.0	10.2	—	—
6e	4	5.2	4.9	—	—
6f	5	6.2	8.3	—	—
6g	6	6.0	—	n.i.	n.i.
6h	6	6.0	—	n.i.	6.0
6i	6	7.0	—	7.0	7.0
6j	—	—	—	—	—
6k	—	—	—	—	—
6l	6	10.0	—	46.0	8.0
6m	n.i.	n.i.	—	n.i.	9.0
6n	n.i.	6.0	—	n.i.	6.0
6o	—	—	—	—	—
6p	—	—	—	—	—

n.i = not inhibited; all zone of inhibition are in mm.

Compounds were found to be inactive on primary screen for their anti-cancer evaluation tests (CRI, Maryland USA).

ACKNOWLEDGEMENT

The authors are thankful to Central Instrumentation Laboratory, Chandigarh for spectra, UGC for research grant, Government Medical College, Microbiology Dept., Nagpur for carrying out antimicrobial activity and National Cancer Institute, Maryland, USA for anticancer activity. The authors are also thankful to Jaswinder Kaur for necessary help (UGC Project).

REFERENCES

1. H. Eck, F. Mueller and S. Wiharheim, *Chem. Abstr.*, **81**, 120676 (1974); T. Veda, J. Sakakibara and J. Nakagami, *Chem. Abstr.*, **101**, 38418 (1984); S. Ozaki, Y. Watanabe, T. Hoshiko, H. Mizuno, K. Ishikawa and H. Mori, *Chem. Abstr.*, **101**, 55035 (1984); J.C. Gage, *J. Chem. Soc.*, 469 (1949); K.M. Ghoneim, F. El-Telbany and R. Youssef, *J. Indian Chem. Soc.*, **53**, 914 (1986).
2. J. Sengupta, *Indian J. Appl. Chem.*, **29**, 3 (1964); Muslin W. Roth and H.H. Erlenmeyer, *Helv. Chim. Acta*, **36**, 36 (1953).
3. F.D. Popp, *J. Org. Chem.*, **26**, 1560 (1961).
4. V.K. Ahluwalia, N. Kalia and S. Bala, *Indian J. Chem.*, **26B**, 700 (1987).
5. B.J. Ghiya and A.G. Doshi, *Curr. Sci. (India)*, **55**, 502 (1986).

(Received: 5 May 1998; Accepted: 15 June 1998)

AJC-1521